Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell 
Invasion and Metastasis in NSCLC

Volz, C.; Breid, S.; Selenz, C.; Zaplatina, A.; Golfmann, K.; Meder, L.; Dietlein, F.; Borchmann, S.; Chatterjee, S.; Siobal, M.; Schottle, J.; Florin, A.; Koker, M.; Nill, M.; Ozretic, L.; Uhlenbrock, N.; Smith, S.; Buttner, R.; Miao, H.; Wang, B.; Reinhardt, H. C.; Rauh, D.; Hallek, M.; Acker-Palmer, Amparo; Heukamp, L. C.; Ullrich, R. T.

doi:10.1016/j.celrep.2020.107568

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC

MPS-Authors

/persons/resource/persons38744

Acker-Palmer, Amparo
Neurovascular interface Group, Max Planck Institute for Brain Research, Max Planck Society;

External Resource

https://www.ncbi.nlm.nih.gov/pubmed/32348765
(Any fulltext)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Volz, C., Breid, S., Selenz, C., Zaplatina, A., Golfmann, K., Meder, L., et al. (2020). Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Rep, 31(4), 107568. doi:10.1016/j.celrep.2020.107568.

Cite as: https://hdl.handle.net/21.11116/0000-0008-0C46-D

Abstract

Anti-angiogenic treatment targeting vascular endothelial growth factor (VEGF)-VEGFR2 signaling has shown limited efficacy in lung cancer patients. Here, we demonstrate that inhibition of VEGFR2 in tumor cells, expressed in approximately 20% of non-squamous non-small cell lung cancer (NSCLC) patients, leads to a pro-invasive phenotype. Drug-induced inhibition of tumor VEGFR2 interferes with the formation of the EphA2/VEGFR2 heterocomplex, thereby allowing RSK to interact with Serine 897 of EphA2. Inhibition of RSK decreases phosphorylation of Serine 897 EphA2. Selective genetic modeling of Serine 897 of EphA2 or inhibition of EphA2 abrogates the formation of metastases in vivo upon VEGFR2 inhibition. In summary, these findings demonstrate that VEGFR2-targeted therapy conditions VEGFR2-positive NSCLC to Serine 897 EphA2-dependent aggressive tumor growth and metastasis. These data shed light on the molecular mechanisms explaining the limited efficacy of VEGFR2-targeted anti-angiogenic treatment in lung cancer patients.